SPONSORED:

Democrats urge Biden FDA to drop in-person rule for abortion pill

Democrats urge Biden FDA to drop in-person rule for abortion pill
© Getty Images

A group of House Democrats pressed the Food and Drug Administration (FDA) Tuesday to lift “medically unnecessary” restriction on the abortion pill that have been in place for several years.

Under the FDA rule, mifepristone, which is used to end early pregnancies and treat early pregnancy loss, can only be dispensed in person, a requirement that has received renewed criticism during the COVID-19 pandemic.

“Imposing this requirement in the midst of a deadly pandemic—one that has disproportionately impacted communities of color across the United States—needlessly places patients and providers in harm’s way, and further entrenches longstanding health inequities,” Committee Chair Carolyn MaloneyCarolyn MaloneyHow ERA is good for the economy Wray suggests limits on FBI social media tracking a 'lesson learned' after Jan. 6 Trump, allies pressured DOJ to back election claims, documents show MORE (D-N.Y.) and other Democrats on the House Oversight and Reform Committee wrote in a letter to acting FDA Commissioner Janet Woodcock.

ADVERTISEMENT

Democratic Reps. Ayanna PressleyAyanna PressleyIt's past time we elect a Black woman governor House Republicans introduce resolution to censure the 'squad' Progressives rally behind Omar while accusing her critics of bias MORE (Mass.), Alexandria Ocasio-CortezAlexandria Ocasio-CortezHillary Clinton backs Shontel Brown in Ohio congressional race Ocasio-Cortez, Gillibrand and Moulton call for more high-speed rail funding in infrastructure package Pelosi picks Democrats for special panel tackling inequality MORE (N.Y.), Katie Porter (Calif.), Rashida TlaibRashida Harbi TlaibHouse Republicans introduce resolution to censure the 'squad' Progressives rally behind Omar while accusing her critics of bias Omar: I wasn't equating terrorist organizations with democratic countries MORE (Mich.), Cori Bush (Mo.), Debbie Wasserman SchultzDeborah (Debbie) Wasserman SchultzOmar feuds with Jewish Democrats Shakespeare gets a congressional hearing in this year's 'Will on the Hill' Theatres are a vital educational, creative and economic resource to communities MORE (Fla.), Jackie SpeierKaren (Jackie) Lorraine Jacqueline SpeierDemocrats call on Blinken to set new sexual misconduct policies at State Department House lawmakers unveil bill to end ban on Postal Service shipments of alcohol Push to combat sexual assault in military reaches turning point MORE (Calif.), Robin KellyRobin Lynne KellyLobbying world Pharmaceutical industry donated to two-thirds of Congress ahead of 2020 elections: analysis Republicans defy mask rules on House floor MORE (Ill.) and Brenda LawrenceBrenda Lulenar Lawrence14 Republicans vote against making Juneteenth a federal holiday Tulsa marks race massacre centennial as US grapples with racial injustice After George Floyd, how much has changed? MORE (Mich.), as well as Del. Eleanor Holmes NortonEleanor Holmes NortonSenate to hold hearing on DC statehood bill Shakespeare gets a congressional hearing in this year's 'Will on the Hill' Constitutional scholars say congressional proclamation could make DC a state MORE (D.C.) signed on to the letter.

Health organizations including the American College of Obstetricians and Gynecologists (ACOG) have long argued that the in-person dispensing requirements impede access to abortion and are medically unnecessary because the drug is safe.

In response to the pandemic, the FDA last year suspended in-person dispensing requirements for other drugs but not for mifepristone, prompting a lawsuit from ACOG.

While lower courts sided with ACOG and temporarily ordered the FDA to pause enforcement of the rule while the lawsuit proceeded, the Supreme Court eventually sided with the Trump administration, which argued the requirements were still necessary.

Courts have not yet ruled on the merits of the case, which is being heard by the 4 th Circuit Court of Appeals.

ADVERTISEMENT

But it’s not yet clear how the Department of Justice will respond to the lawsuit now that the Biden administration has taken over.

The FDA could also agree to suspend the in-person requirements, which would make the case moot, according to the American Civil Liberties Union, which is representing ACOG in the lawsuit.

Biden has not yet named a nominee to lead the FDA.

“The Biden-Harris Administration has vowed to follow the science, and the evidence is crystal clear that this in-person pick-up requirement is senseless and dangerous. It’s time to act,” Julia Kaye, staff attorney at the ACLU Reproductive Freedom project and lead counsel on the case, said in a statement.